Endometrial cancer (EC) is the most common gynecological malignancy with high disease burden especially in advanced stages of the disease. Our study investigated the metabolomic profile of EC patient's serum with the aim of identifying novel diagnostic biomarkers that could be used especially in early disease detection. Using targeted metabolomic serum profiling based on HPLC-TQ/MS, women with EC (n = 15) and controls (n = 21) were examined for 232 endogenous metabolites. Top performing biomarkers included ceramides, acylcarnitines and 1-methyl adenosine. Top 4 biomarkers combined achieved 94% sensitivity with 75% specificity with AUC 92.5% (CI 90.5-94.5%). Individual markers also provided significant predictive values: C16-ceramide achieved sensitivity 73%, specificity 81%, AUC 0.83, C22-ceramide sensitivity 67%, specificity 81%, AUC 0.77, hydroxyhexadecenoylcarnitine sensitivity 60%, specificity 96%, AUC 0.76 and 1-methyladenosine sensitivity 67%, specificity 81%, AUC 0.75. The individual markers, however, did not reach the high sensitivity and specificity of the 4-biomarker combination. Using mass spectrometry targeted metabolomic profiling, ceramides, acylcarnitines and 1-methyladenosine were identified as potential diagnostic biomarkers for EC. Additionally, these identified metabolites may provide additional insight into cancer cell metabolism.
2 March 2021 in Journal of Cellular and Molecular Medicine
Cell lines are widely used for various research purposes including cancer and drug research. Recently, there have been studies that pointed to discrepancies in the literature and usage of cell lines. That is why we have prepared a comprehensive overview of the most common gynaecological cancer cell lines, their literature, a list of currently available cell lines, and new findings compared with the original studies. A literature review was conducted via MEDLINE, PubMed and ScienceDirect for reviews in the last 5 years to identify research and other studies related to gynaecological cancer cell lines. We present an overview of the current literature with reference to the original studies and pointed to certain inconsistencies in the literature. The adherence to culturing rulesets and the international guidelines helps in minimizing replication failure between institutions. Evidence from the latest research suggests that despite certain drawbacks, variations of cancer cell lines can also be useful in regard to a more diverse genomic landscape.
This study evaluates the predictive value of Anti-Müllerian Hormone (AMH) levels on outcomes in medically assisted reproduction (MAR), with a focus on women of late reproductive age. AMH, produced by granulosa cells in ovarian follicles, serves as an important indicator of ovarian reserve. A retrospective cohort analysis was conducted, encompassing 4891 MAR cycles, to assess the age-specific predictive value of AMH for clinical pregnancy. The results indicate that AMH is significantly correlated with clinical pregnancy outcomes (p < 0.01) and demonstrates potential predictive value in women over 35 years of age, with its predictive capacity increasing notably with age (AUC = 0.62–0.69). However, in younger women, the correlation between AMH levels and MAR outcomes is weaker (AUC = 0.48–0.53). These findings highlight the importance of integrating AMH measurements with age when assessing fertility potential and tailoring MAR treatments, particularly for women approaching the end of their reproductive lifespan.